scancell 产品代理
scancell 产品代理
癌症免疫治疗市场是生物制药行业增长最快的市场之一，预计到2022年价值1000亿美元。免疫疗法正在评估大多数癌症适应症，与化疗相比，其无与伦比的疗效和相对较低的毒性已经导致许多癌症治疗的范式转变。然而，肿瘤往往成功地避开了人体自身的自然防御机制，即免疫系统，并非所有患者都能对基于检查点抑制剂的免疫疗法做出反应。因此，治疗性疫苗有可能通过启动将无反应的肿瘤或所谓的“冷”肿瘤转化为“热”肿瘤的免疫反应来提高受益患者的比例。
SCIB1
SCIB2
Modi-1
Modi-2
SCOV1 & SCOV2 (COVIDITY)
Scancell is a clinical-stage immuno-oncology company which was founded in 1997 on research led by Professor Lindy Durrant at the University of Nottingham. The Company is operating at the forefront of immuno-oncology, an exciting field of cancer research which involves the development of immunotherapies to harness the body’s ability to generate and sustain an effective immune response against cancer.
The cancer immunotherapy market is one of the most rapidly growing markets within the biopharmaceutical industry, estimated to be worth USD100 billion by the year 2022. Immunotherapies are being evaluated in most cancer indications and their unrivalled efficacy and relatively low toxicity profile compared to chemotherapy is already leading to paradigm shifts in the treatment of many cancers. However, tumours often successfully evade the body’s own natural defence mechanism, the immune system, and not all patients are able to respond to checkpoint inhibitor-based immunotherapies. Therapeutic vaccines therefore have the potential to improve the proportion of patients who are able to benefit by initiating immune responses that convert unresponsive tumours, or so-called “cold” tumours, into “hot” ones.
The commercial potential of Scancell’s products will be defined by clinical data, either as monotherapies or in combination with checkpoint inhibitors, designed to provide increased and durable responses in patients without compromising safety and to address the unmet needs in hard to treat cancers. Scancell’s three technology platforms, ImmunoBody®, Moditope® and AvidiMab™, each offers a unique approach to cancer therapy to address all of these criteria.
As the COVID-19 pandemic has unfolded, Scancell has evaluated how it can best contribute its expertise and resources to help in the global response. Vaccines are the long-term solution and the company believes its combined high avidity T cell and neutralising antibody approach has the potential to produce a second-generation vaccine that will generate an effective and durable immune response to COVID-19. Scancell has therefore initiated its COVIDITY programme to develop a COVID-19 vaccine in collaboration with scientists at the University of Nottingham and Nottingham Trent University.
